US FDA reform top of the Congressional agenda
This article was originally published in Clinica
Executive Summary
The rhetoric could be that of January 1996. Republican leaders in both the House and Senate insist that overhauling the US FDA is a high priority in the next (105th) Congress and could be taken up early in the first session, which begins in January. But David Kessler's announcement in November that he is to step down as commissioner adds an unknown factor to what would anyway be a politically convoluted process. Opinion is divided as to how Dr Kessler's lame duck status will affect FDA reform.